Research progress of maintenance therapy for cervical cancer

doi:10.3760/cma.j.cn371439-20220602-00082

Abstract

Abstract:

Cervical cancer is a common malignant tumor that threatens women's life and health. Among them, the prognosis of recurrent or advanced cervical cancer is poor, and such patients often receive surgical treatment, radiotherapy, chemotherapy, etc., which makes it more difficult to choose a treatment plan. Even after the most effective treatment methods, the treatment failure rate of advanced cervical cancer is still high. Thanks to the research progress of tumor cell signaling pathway-related targets and immunotherapy, especially immune checkpoint inhibitors, new breakthroughs have been made in cervical cancer maintenance therapy. Targeted maintenance therapy, immune maintenance therapy, and multi-drug combination maintenance therapy are currently popular areas of cervical cancer maintenance therapy.

Key words: Uterine cervical neoplasms, Recurrence, Neoplasm metastasis, Maintenance treatment

Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.

References 39

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84. DOI: 10.6004/jnccn.2019.0001. doi: 10.6004/jnccn.2019.0001
[3]	Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer[J]. Radiother Oncol, 2018, 127(3): 404-416. DOI: 10.1016/j.radonc.2018.03.003. doi: S0167-8140(18)30135-X pmid: 29728273
[4]	Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014, 370(8): 734-743. DOI: 10.1056/NEJMoa1309748. doi: 10.1056/NEJMoa1309748
[5]	Leath CA 3rd, Straughn JM Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials[J]. Gynecol Oncol, 2013, 129(1): 251-257. DOI: 10.1016/j.ygyno.2012.12.035. doi: 10.1016/j.ygyno.2012.12.035
[6]	Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)[J]. Lancet, 2017, 390(10103): 1654-1663. DOI: 10.1016/S0140-6736(17)31607-0. doi: 10.1016/S0140-6736(17)31607-0
[7]	Godoy-Ortiz A, Plata Y, Alcaide J, et al. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients[J]. Clin Transl Oncol, 2018, 20(7): 922-927. DOI: 10.1007/s12094-017-1808-x. doi: 10.1007/s12094-017-1808-x pmid: 29222647
[8]	Suzuki K, Nagao S, Shibutani T, et al. Phase Ⅱ trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer[J]. Gynecol Oncol, 2019, 154(3): 554-557. DOI: 10.1016/j.ygyno.2019.05.018. doi: 10.1016/j.ygyno.2019.05.018
[9]	Zhu J, Song C, Zheng Z, et al. Anlotinib in Chinese patients with recurrent advanced cervical cancer: a prospective single-arm, open-label phase Ⅱ trial[J]. Front Oncol, 2021, 11: 720343. DOI: 10.3389/fonc.2021.720343. doi: 10.3389/fonc.2021.720343
[10]	Xia X, Jiang W, Qi W, et al. Clinical efficacy and safety of apatinib for the treatment of patients with metastatic, recurrent cervical cancer after failure of radiotherapy and first-line chemotherapy: a prospective study[J]. Oncol Res Treat, 2020, 43(12): 649-655. DOI: 10.1159/000510355. doi: 10.1159/000510355
[11]	Li N, Wang Z, Yuan G, et al. An oral small molecule VEGFR2 inhibitor, apatinib, in patients with recurrent or refractory cervical cancer: a real world study[J]. J Oncol, 2020, 2020: 3852373. DOI: 10.1155/2020/3852373. doi: 10.1155/2020/3852373
[12]	Xiao Y, Cheng H, Wang L, et al. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study[J]. J Gynecol Oncol, 2020, 31(1): e2. DOI: 10.3802/jgo.2020.31.e2. doi: 10.3802/jgo.2020.31.e2
[13]	Yang H, Chen M, Mei Z, et al. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: a retrospective study[J]. Cancer Med, 2021, 10(13): 4282-4290. DOI: 10.1002/cam4.3966. doi: 10.1002/cam4.3966
[14]	Zhang L, Chen L, Yu H. Phase Ⅱ study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients[J]. Invest New Drugs, 2020, 38(4): 1186-1191. DOI: 10.1007/s10637-019-00858-5. doi: 10.1007/s10637-019-00858-5
[15]	de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or meta static solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(3): 383-393. DOI: 10.1016/S1470-2045(18)30859-3. doi: 10.1016/S1470-2045(18)30859-3
[16]	Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2021, 22(5): 609-619. DOI: 10.1016/S1470-2045(21)00056-5. doi: 10.1016/S1470-2045(21)00056-5
[17]	A randomized, open-label, phase 3 trial of tisotumab vedotin vs investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer[EB/OL]. [2021-2-22][2022-7-26]. https://clinicaltrials.gov/ct2/show/NCT04697628?term=NCT04697628&draw=2&rank=1.
[18]	Vergote IB, Concin N, Mirza MR, et al. 1064TiP—phase Ⅰ/Ⅱ trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)[J]. Ann Oncol, 2019, 30(Supplement 5): v433-v434. DOI: 10.1093/annonc/mdz250.072. doi: 10.1093/annonc/mdz250.072
[19]	A phase 1b/2 open-label trial of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination with other agents in subjects with recurrent or stage ⅣB cervical cancer[EB/OL]. [2019-2-27] [2022-5-20]. https:/clinicaltrials.gov/ct2/show/NCT03786081?term=NCT03786081&draw=2&rank=1.
[20]	Benson R, Pathy S, Kumar L, et al. Locally advanced cervical cancer—neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: a phase Ⅱ study[J]. J Cancer Res Ther, 2019, 15(6): 1359-1364. DOI: 10.4103/jcrt.JCRT_39_18. doi: 10.4103/jcrt.JCRT_39_18 pmid: 31898673
[21]	Pignata S, Scambia G, Lorusso D, et al. The MITO CERV-2 trial: a randomized phase Ⅱ study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer[J]. Gynecol Oncol, 2019, 153(3): 535-540. DOI: 10.1016/j.ygyno.2019.03.260. doi: S0090-8258(19)30495-0 pmid: 30979589
[22]	Carlson JJ, Italiano A, Brose MS, et al. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer[J]. Am J Manag Care, 2022, 28(2 Suppl): S26-S32. DOI: 10.37765/ajmc.2022.88845. doi: 10.37765/ajmc.2022.88845
[23]	Thaker PH, Salani R, Brady WE, et al. A phase Ⅰ trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)[J]. Ann Oncol, 2017, 28(3): 505-511. DOI: 10.1093/annonc/mdw635. doi: 10.1093/annonc/mdw635 pmid: 27998970
[24]	Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ⅰb KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36): 4035-4041. DOI: 10.1200/JCO.2017.74.5471. doi: 10.1200/JCO.2017.74.5471
[25]	Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265. doi: 10.1200/JCO.18.01265
[26]	Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase Ⅰ/Ⅱ CheckMate 358 trial[J]. J Clin Oncol, 2019, 37(31): 2825-2834. DOI: 10.1200/JCO.19.00739. doi: 10.1200/JCO.19.00739 pmid: 31487218
[27]	Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer[J]. N Engl J Med, 2022, 386(6): 544-555. DOI: 10.1056/NEJMoa2112187. doi: 10.1056/NEJMoa2112187
[28]	Prospective randomized phase Ⅱ trial comparing doxorubicin alone versus atezolizumab alone versus doxorubicin and atezolizumab in recurrent cervical cancer[EB/OL]. [2017-8-30] [2021-1-27]. https://clinicaltrials.gov/ct2/show/NCT03340376?term=NCT03340376&draw=2&rank=1.
[29]	Mayadev J, Nunes AT, Li M, et al. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase Ⅲ, randomized, double-blind, multicenter study[J]. Int J Gynecol Cancer, 2020, 30(7): 1065-1070. DOI: 10.1136/ijgc-2019-001135. doi: 10.1136/ijgc-2019-001135 pmid: 32447296
[30]	Update on CALLA phase Ⅲ trial of concurrent use of imfinzi and chemoradiotherapy in locally advanced cervical cancer[EB/OL]. [2022-3-24] [2022-5-20]. https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-im-finzi.html.
[31]	Lheureux S, Butler MO, Clarke B, et al. Association of ipili-mumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma[J]. JAMA Oncol, 2018, 4(7): e173776. DOI: 10.1001/jamaoncol.2017.3776. doi: 10.1001/jamaoncol.2017.3776
[32]	A phase 2, multicenter, single arm, open label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer[EB/OL]. [2020-7-15] [2022-5-28]. https://clinicaltrials.gov/ct2/show/NCT04380805?term=NCT04380805&draw=2&rank=1.
[33]	A multicenter, open-label, phase Ⅱ study of AK104(an anti-PD-1 and anti-CTLA-4 bispecific antibody) in the treatment of recurrent or metastatic cervical cancer[EB/OL]. [2021-4-01] [2022-5-29]. https://clinicaltrials.gov/ct2/show/NCT04868708?term=NCT04868708&draw=2&rank=1.
[34]	double-blind, placebo-controlled phase Ⅲ study to evaluate AK104 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer[EB/OL]. [2021-8-27] [2022-4-27]. https://clinicaltrials.gov/ct2/show/NCT04982237?term=NCT04982237&draw=2&rank=1.
[35]	O'Malley DM, Oaknin A, Monk BJ, et al. LBA34 single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): preliminary results of two independent phase Ⅱ trials[J]. Ann Oncol, 31(Supplement 4):S1164-S1165. DOI: 10.1016/j.annonc.2020.08.2264. doi: 10.1016/j.annonc.2020.08.2264
[36]	Monk BJ, Tewari KS, Hasegawa CK, et al. Patient-reported outcomes from the phase 3 randomized, double-blind, KEYNOTE-826 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer[R]. Phoenix: The Society of Gynecologic Oncology (SGO)2022 Annual Meeting on Women’s Cancer, 2022.
[37]	Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase Ⅱ trial[J]. J Clin Oncol, 2022, 40(16): 1795-1805. DOI: 10.1200/JCO.21.02091. doi: 10.1200/JCO.21.02091
[38]	Lan C, Shen J, Wang Y, et al. Camrelizumab Plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(34): 4095-4106. DOI: 10.1200/JCO.20.01920. doi: 10.1200/JCO.20.01920
[39]	Friedman CF, Snyder Charen A, Zhou Q, et al. Phase Ⅱ study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer[J]. J Immunother Cancer, 2020, 8(2): e001126. DOI: 10.1136/jitc-2020-001126. doi: 10.1136/jitc-2020-001126